Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis

Journal of Dermatology

Volumn 37, Issue 9, 2010, Pages 801-806

  Ohtsuka, Tsutomu ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

high sensitivity C reactive protein; interleukin 6; systemic sclerosis

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; INTERLEUKIN 6; LACTOSE; LACTOSE DEHYDROGENATE; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; NEPHELOMETRY; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 77956203111     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00883.x     Document Type: Article

References (21)

1. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): A study of fifty-eight autopsy cased and fifty-eight matched controls. Am J Med 1969 46 : 428 440.
2. Sakkas LI, Lazaros I. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005 38 : 113 116.
3. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003 15 : 778 784.
4. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995 13 : 17 22.
5. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998 25 : 308 313.
6. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005 143 : 918 920.
7. Bohgaki T, Amasaki Y, Nishimura N et al. Up regulated expression of tumor necrosis factor-α converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis 2005 64 : 1165 1173.
8. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 103 : 1813 1818.
9. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980 23 : 581 590.
10. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988 15 : 202 205.
11. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000 101 : 1372 1378.
12. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001 27 : 140 146.
13. Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004 138 : 540 546.
14. Becvar R, Stork J, Pesakova V et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann NY Acad Sci 2005 1051 : 404 412.
15. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006 33 : 275 284.
16. Takemura H, Suzuki H, Fujisawa H et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998 25 : 1534 1539.
17. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998 25 : 296 301.
18. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999 38 : 612 617.
19. Giacomelli R, Cipriani P, Danese C et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol 1996 23 : 291 296.
20. Crestani B, Seta N, De Bandt M et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994 149 : 1260 1265.
21. Kerner A, Avizohar O, Sella R et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005 25 : 193 197.